Lacosamide

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released November 2, 2010; last updated September 20, 2016; expires September 20, 2019

Historical note and terminology

Lacosamide, with the chemical name of (R)N-acetyl-D,L-alanine benzyl-3-methoxypropionamide, is a functionalized amino acid with novel mechanisms of action. It has been specifically developed as an antiepileptic drug for the adjunctive treatment of partial-onset seizures. It was approved in the United States by the FDA in 2008 and was also approved in the European Union in the same year. It is marketed under the trade name of “Vimpat” (UCB Pharmaceuticals). The DEA has placed lacosamide into schedule V of the Controlled Substances Act. It is also being developed for the treatment of diabetic neuropathic pain.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.